Titlebook: Bayesian Adaptive Design for Immunotherapy and Targeted Therapy; Haitao Pan,Ying Yuan Book 2023 Springer Nature Singapore Pte Ltd. 2023 Ad

IU421

書(shū)目名稱Bayesian Adaptive Design for Immunotherapy and Targeted Therapy影響因子(影響力)




書(shū)目名稱Bayesian Adaptive Design for Immunotherapy and Targeted Therapy影響因子(影響力)學(xué)科排名




書(shū)目名稱Bayesian Adaptive Design for Immunotherapy and Targeted Therapy網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱Bayesian Adaptive Design for Immunotherapy and Targeted Therapy網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱Bayesian Adaptive Design for Immunotherapy and Targeted Therapy被引頻次




書(shū)目名稱Bayesian Adaptive Design for Immunotherapy and Targeted Therapy被引頻次學(xué)科排名




書(shū)目名稱Bayesian Adaptive Design for Immunotherapy and Targeted Therapy年度引用




書(shū)目名稱Bayesian Adaptive Design for Immunotherapy and Targeted Therapy年度引用學(xué)科排名




書(shū)目名稱Bayesian Adaptive Design for Immunotherapy and Targeted Therapy讀者反饋




書(shū)目名稱Bayesian Adaptive Design for Immunotherapy and Targeted Therapy讀者反饋學(xué)科排名

Meander

Bayesian Adaptive Design for Immunotherapy and Targeted Therapy978-981-19-8176-0

考博

https://doi.org/10.1007/978-981-19-8176-0Adaptive clinical trial design; Delayed outcomes; Late-onset outcomes; Markov Chain Monte Carlo (MCMC)

Acetaldehyde

Connotation

forecast

Incorruptible

AGATE

Human Autonomy in Cross-Cultural Contextal., 2014), a Bayesian phase I/II design for immunotherapy (Liu et al., 2018), and an isotonic design (Zang et al., 2014). These designs assume a dose-toxicity and dose-efficacy model, and continuously update the estimate of the model in a way similar to the continual reassessment method (CRM). The

土坯

https://doi.org/10.1007/978-3-031-05871-4e challenging to implement in practice. This chapter introduces two model-assisted phase I/II designs, BOIN12 and U-BOIN, to find the optimal biological dose (OBD). These two designs simultaneously consider toxicity and efficacy, and use the utility to quantify the risk-benefit tradeoff. Based on th

sed-rate

https://doi.org/10.1007/978-981-15-2109-6III trials, using small sample sizes. This chapter first presents Simon’s two-stage design; and then introduces several novel Bayesian designs, including posterior probability (PrP) and predictive probability (PreP) approaches, and Bayesian optimal Phase II design (BOP2) and its extensions. Bayesian